Senti Biosciences enters merger agreement with Celadon affiliate; stockholders to receive CVRs for SENTI-202 milestones

Senti Biosciences, Inc.

Celadon affiliate to acquire substantially all of Senti's business and pipeline via merger; Senti to remain public with streamlined structure.
Stockholders will receive contingent value rights (CVRs) with potential payments up to $60M based on SENTI-202 BLA filing, FDA approval, and net sales milestones.
Preliminary cash and cash equivalents of $6.5M as of June 30, 2026; combined with $6M additional funding from Celadon expected to fund operations through Q4 2026.
Merger subject to stockholder approval and other conditions; expected to close in Q3 2026.
Celadon, already largest stockholder with 54.6% ownership, could increase to up to 77.5% if additional notes are issued and exchanged.

item 1.01 item 2.02 item 5.01 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.